LUNAC Therapeutics is a Leeds‑based drug discovery company spun out of the University of Leeds to identify and develop next‑generation anticoagulants that target activated Factor XII. The company’s core program focuses on inhibiting Factor XII, which the team believes drives pathological clot formation without affecting hemostasis, and individuals lacking Factor XII do not exhibit bleeding symptoms. LUNAC was founded on IP generated by Prof Helen Philippou and Dr Richard Foster, building on a decade of academic research supported by the Wellcome Trust, the British Heart Foundation and the Medical Research Council. The company intends to advance Factor XII‑targeted therapeutics as differentiated anticoagulant options with reduced bleeding risk. Financially, LUNAC announced a first close of its Series A financing for £2.65M led by Epidarex Capital and the University of Leeds to progress its discovery programs.

Total raised

$3M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2019